In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Lilly pays Icos $75mm up front to establish JV

Executive Summary

Lilly will pay Icos (uf)$75mm up front to share 50-50 N. American and European profits from the sale of Icos' Phase II oral anti-impotence drug IC351. Lilly has also agreed to pay Icos an added $52.5mm to form a JV to develop the compound.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Contract
    • Joint Venture
    • Includes Royalty or Profit Split Information
    • R+D and Marketing-Licensing

Related Companies

Advertisement
UsernamePublicRestriction

Register